How is calcitonin dosed?
| Product | Supply | Labelled dose and route |
|---|---|---|
| Injection, symptomatic Paget's disease of bone | 2 mL multi-dose vial, 200 USP Units per mL1 | 100 USP Units (0.5 mL) a day, subcutaneous or intramuscular; only if alternative treatments fail or are not suitable1 |
| Injection, postmenopausal osteoporosis in women greater than 5 years postmenopause | Same vial | 100 USP Units (0.5 mL) a day, subcutaneous or intramuscular; only if alternatives are not suitable; fracture reduction not demonstrated; minimum effective dose for preventing vertebral bone mineral density loss not established1 |
| Injection, early treatment of hypercalcemia (start) | Same vial | 4 USP Units/kg body weight every 12 hours, subcutaneous or intramuscular; may be increased to 8 USP Units/kg every 12 hours after one or two days without a satisfactory response1 |
| Injection, hypercalcemia (maximum) | Same vial | At most 8 USP Units/kg every 6 hours, if the response remains unsatisfactory after two more days1 |
| Nasal solution, postmenopausal osteoporosis in women greater than 5 years postmenopause | 3.7 mL bottle, 2200 International Units per mL; 0.09 mL (200 International Units) per spray2 | 1 spray (200 International Units) a day, alternating nostrils daily; only if alternatives are not suitable; fracture reduction not demonstrated2 |
The US labels give 100 USP Units (0.5 mL) per day by injection for symptomatic Paget's disease of bone, and 1 spray (200 International Units) per day intranasally for postmenopausal osteoporosis in women greater than 5 years postmenopause, for patients for whom alternative treatments are not suitable.12
Labelled doses and supply
The table is set at the top of the page
Neither label gives a mixing step, and the injection label lists no intravenous dose.12 Above 2 mL, the injection label prefers intramuscular injection, spread across multiple sites.1
Before the first dose, the label has the bottle reach room temperature and the new pump primed upright until a full spray is released.2 Each day the label has the head upright and the pump firmly depressed, with no priming before each daily dose.2
What trials used
The nasal trials below used 50 to 400 IU a day.34 Separately, the nasal label's overdosage section says chronic doses up to 600 International Units per day were studied without serious adverse effects.2
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Chesnut (PROOF), 2000 | Nasal spray 100, 200 or 400 IU daily, or placebo, all with calcium (1,000 mg) and vitamin D (400 IU) daily | 1,255 postmenopausal women with established osteoporosis | 5 years; 783 completed 3 years, 511 completed 5 years3 |
| Thamsborg, 1991 | Nasal spray placebo, 50, 100 or 200 IU per day | Forty postmenopausal women with a former Colles' fracture | 1 year4 |
| Tekeoğlu, 2005 | Open-label; nasal spray 200 IU/day continuously, 200 IU/day on alternating 15 days per month, or on 10 days consecutively per month with 20 days a month rest, each with elementary calcium (500 mg) and 1-alpha hydroxyvitamin D3 (0.25 microg) | 120 postmenopausal osteoporotic participants (ages 50 to 65), 40 per group | 1 year5 |
In PROOF (Chesnut, 2000, 1,255 women) the 200 IU dose, the primary comparison, reduced new vertebral fractures by 33% against placebo, while the 100 IU and 400 IU arms did not differ significantly; lumbar spine bone density rose in all active groups.3
Cycles and how long calcitonin is used
Neither US label gives a cycle; each calls for periodic re-evaluation of continued therapy because of a possible malignancy association.12 Cyclic nasal regimens come from trials only, and in their 2005 open-label trial of 120 postmenopausal osteoporotic participants the Tekeoğlu authors concluded the 10-day regimen was as effective as the other two.5
In 2012 the EMA said calcitonin would only be available as a solution for injection and infusion, limited to the shortest possible time and the minimum effective dose: two weeks (at most four) for sudden immobilisation bone loss, and normally 3 months (6 in exceptional circumstances) for Paget's disease when alternatives fail or are not suitable.6 It cited a cancer risk 0.7% to 2.4% higher than placebo in long-term trials, with higher rates for intranasal calcitonin.6 In the EU the nasal spray, used only in osteoporosis, was recommended for withdrawal, while the US nasal label still gives 1 spray (200 International Units) per day.62
Storage
The injection label says to store the vial in a refrigerator at 2° to 8°C and protect it from freezing, and it gives no use-by time after the vial is punctured.1 The nasal label says to store unopened bottles in the refrigerator at 2°C to 8°C and avoid freezing.2 The nasal label says to store a bottle in use upright at room temperature, 20°C to 25°C, for up to 35 days, and to discard it after 30 doses.2
Frequently asked questions
Is calcitonin dosed differently in renal failure?
Neither label gives a renal-failure dose; the injection label says dose selection for an elderly patient is to be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and the nasal label says safety and effectiveness in pediatric patients have not been established.12
How many units on a U-100 syringe is a calcitonin dose?
The injection label gives the volume, 0.5 mL for 100 USP Units, and no syringe mark.1
References
- DailyMed. These highlights do not include all the information needed to use MIACALCIN INJECTION safely and effectively. See full prescribing information for MIACALCIN INJECTION. MIACALCIN ® (calcitonin salmon) injection, synthetic, for subcutaneous or intramuscular use Initial U.S. Approval: 1975. 2024. dailymed.nlm.nih.gov
- DailyMed. These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SOLUTION safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SOLUTION . CALCITONIN SALMON nasal solution, for intranasal use (Synthetic Origin) Initial U.S. Approval: 1975. 2026. dailymed.nlm.nih.gov
- PubMed. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. 2000. pubmed.ncbi.nlm.nih.gov
- PubMed. Effect of different doses of nasal salmon calcitonin on bone mass. 1991. pubmed.ncbi.nlm.nih.gov
- PubMed. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis. 2005. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency. European Medicines Agency recommends limiting long-term use of calcitonin medicines. ema.europa.eu